Advertisement

European Journal of Clinical Pharmacology

, Volume 74, Issue 2, pp 243–244 | Cite as

Perampanel-associated self-harm ideation after dosage increase

  • Farid Kheloufi
  • Anne Default
  • Bruno Perrouty
  • Olivier Blin
  • Joëlle Micallef
Letter to the Editor

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Huber B (2014) Increased risk of suicidality on perampanel (Fycompa®)? Epilepsy Behav behaviour 31:71–72CrossRefGoogle Scholar
  2. 2.
    Coyle H, Clough P, Cooper P, Mohanraj R (2014) Clinical experience with perampanel: focus on psychiatric adverse effects. Epilepsy Behav 41:193–196CrossRefPubMedGoogle Scholar
  3. 3.
  4. 4.
    Gidal BE, Ferry J, Majid O, Hussein Z (2013 Aug) Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia 54(8):1490–1497CrossRefPubMedGoogle Scholar
  5. 5.
    Eisai Europe Ltd. Fycompa 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg film-coated tablets. EU summary of product characteristics. 2015. http://ec.europa.eu. Accessed 26 July 2017

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Farid Kheloufi
    • 1
    • 2
  • Anne Default
    • 1
    • 2
  • Bruno Perrouty
    • 3
  • Olivier Blin
    • 1
    • 2
  • Joëlle Micallef
    • 1
    • 2
  1. 1.Regional Pharmacovigilance Centre of Marseille Provence Corse, Department of Clinical Pharmacology and PharmacovigilanceAssistance Publique Hôpitaux de MarseilleMarseilleFrance
  2. 2.Service de Pharmacologie Clinique et Pharmacovigilance, Pharmacologie intégrée et Interface Clinique Industrielle, Institut des Neurosciences, CNRS 7289Assistance Publique Hôpitaux de Marseille, Aix Marseille UniversitéMarseilleFrance
  3. 3.Cabinet de neurologieCarpentrasFrance

Personalised recommendations